Interesting COVID-19 Therapeutic Approach

In an upcoming paper by Hoffman et al the authors note: 

The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2- S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.

We could argue that a multi-therapeutic "cocktail" as above may have a powerful and effective treatment for aggressive COVID-19. This is merely a guess based upon the facts. It stops the virus and inhibits the cytokine storm. This paper should be examined.

Unlike the current DC based experts, one cannot keep the economy closed waiting for an immunization when approved treatments may be at hand.